Medivation Inc news

   Watch this stock
Showing stories 11 - 20 of about 91   

Articles published

MDVN 81.44
price chart
Medivation working with JPMorgan on takeover approaches: sources
(Reuters) - Medivation Inc MDVN.O has been working with investment bank JPMorgan Chase & Co (JPM.N) to handle interest from other companies in a potential acquisition, but it has no plans to sell itself, according to people familiar with the matter.
Medivation Said to Hire Advisers to Defend Against Takeover  Bloomberg
Jennifer Jarrett to Join Medivation as Chief Financial Officer  Marketwired (press release)
Medivation Proxy Shows Pfizer Battled Four Bidders to Seal a Deal
A document filed after trading Tuesday by Medivation Inc. (MDVN) discloses that the battle for the cancer drug developer was as competitive as it was made out to be during the several weeks before the company finally revealed an agreement to be ...
3 Stocks Up Over 1000% in the Past 5 Years  Motley Fool
Why Pfizer Remains Attractively Valued With Medivation  Forbes
Medivation Reports Second Quarter 2016 Financial Results
SAN FRANCISCO, CA--(Marketwired - August 09, 2016) - Medivation, Inc. ( NASDAQ : MDVN) today reported its financial results for the quarter ended June 30, 2016 and reaffirmed full-year 2016 financial guidance.
Medivation (MDVN) David T. Hung on Q2 2016 Results - Earnings Call Transcript  Seeking Alpha
Sanofi makes $9.3-billion bid for San Francisco drug company Medivation
Drug maker Sanofi says it has made a $9.3-billion bid for San Francisco pharmaceutical firm Medivation, part of the firm's effort to expand its portfolio of cancer treatments.
Sanofi Makes $9.3 Billion Bid for Medivation  Wall Street Journal
UC, Medivation Argue Old Fights Decide Drug Royalty Row
At issue was the 2005 agreement that licensed the university's molecular compound patent to Medivation and how it applied to the drug company's contract allowing Astellas Pharma Inc to make the prostate cancer drug Xtandi. The school seeks 10 percent ...
Medivation's stock soars after Pfizer buyout deal
Shares of Medivation Inc. mdvn soared 19% in premarket trade Monday, after the developer of cancer treatments confirmed an agreement to be acquired by Pfizer Inc. PFE, +1.52% in a deal valued at $14 billion.
Pfizer expects to close Medivation buyout in 3Q
Pfizer Inc. says Medivation also has a promising pipeline of cancer drugs in late-stage clinical development. That includes the potential breast cancer treatment talazoparib and a potential lymphoma drug.
UC, Medivation Settle Drug Royalty Row On Eve Of Trial
The suit centered around a 2005 agreement that licensed the university's molecular compound patent to Medivation. The school sought 10 percent of the money Medivation received from sublicensing the compound to Astellas Pharma Inc, which makes the ...
Pfizer Completes Acquisition of Medivation
Pfizer Inc. (PFE) today announced the successful completion of its acquisition of Medivation, Inc.(MDVN). As of the tender offer expiration, 115,574,041 shares of Medivation common stock were validly tendered, representing approximately 69.1% of the ...
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed ...
NEW YORK, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Medivation, Inc. (“Medivation” or the “Company”) (Nasdaq:MDVN) in the United States District Court for the ...